HROW Harrow, Inc. - Common Stock
$41,66
Prezzo · Ago 19, 2026
Fondamentali al Ago 10, 2026
Intervallo 52 sett.
$29–$55
50% of range
Rating Analisti
BUY
14 analysts
Prezzo Obiettivo
$68
+62% upside
P/E (TTM)
-297.5
ROE
-8.4%
Margine di Profitto Netto
-1.9%
Informazioni su Harrow, Inc. - Common Stock Panoramica della società da Wikipedia
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Leggi di più
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
Administration and drug pricing advocacy
The company's founder and chief executive officer is Mark L. Baum, a lawyer by training. Baum has been working in the HIV-related pharmacy field since 1999. Baum has been an advocate for drug pricing and patient advocacy, debating former US congressman James Greenwood on this issue at the Oxford Union debating society. In 2016, Baum authored a monograph on drug pricing and has written about pharmaceutical market monopolies in The Wall Street Journal.
Harrow, through its ImprimisRx subsidiary, has sought to create competition for drugs that companies have monopolies through regulatory or other means by marketing new formulations as a compounding pharmacy. This strategy would allow patient access to certain lower cost medication provided, among other conditions, a patient's physician believed such a formulation was best suited for a patient's needs.
In 2015, the company gained international attention when it compounded a pyrimethamine and leucovorin combination formulation which it argued may offer a low-cost, US$1 per pill, "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000 percent by Martin Shkreli and Turing Pharmaceuticals. In December 2015, Express Scripts accepted the company's product into its formulary.
In 2016, it introduced a lower cost version of tiopronin, and was said to have been working on a version of Mylan's EpiPen. The EpiPen competitor's price target was US$100 for a pair of injectors.
In October 2015, Anthony Principi, a former United States Secretary of Veterans Affairs, was elected to the company's board of directors.
ImprimisRx compounding business
Through its compounding subsidiary ImprimisRx, the company was the first pharmaceutical compounding company to make cGMP ophthalmic eye drops and other sterile compounded products available at a national scale through its FDA-registered outsourcing facility.
ImprimisRx's primary business is that of compounding drugs; that is, combining or altering the formulation of existing drugs to market them to specific populations. As of 2015, the company's business model was driven by development and sale of inexpensive alternatives to off-patent medicines where there was previously only a single manufacturer who could therefore charge outsize prices.
In August 2020, ImprimisRx announced that it was expanding its business beyond compounded drugs and that through a partnership with EyePoint Pharmaceuticals, it would begin to sell Dexycu, an FDA-approved steroid product.
As of 2020, Imprimis operated two pharmaceutical production and distribution facilities, both of which are located in Ledgewood, New Jersey. The company has licenses to operate federally, through the US DEA, and through state pharmacy boards in all 50 of the United States.
Litigation
In 2017, after launching a $49 per month low-cost compounded cyclosporine-A formulation as a potential competitor to Restasis and a glaucoma eye drop program called Simple Drops, the company, alongside Sinceres, became the target of a suit from Allergan for claims connected to supposed false and misleading marketing statements.
The company responded, calling Allergan a "professional litigant" and stating, "Allergan, one of the most powerful Big Pharma companies in the world, has filed this lawsuit against one of the smallest pharmaceutical companies in the world, to snuff out any competition to its high drug price strategies. Allergan, a true Goliath, is bent on ensuring that Americans continue to pay the highest possible prices for its drugs."
During the lawsuit, it was revealed that Allergan engaged in significant lobbying to FDA, state boards of pharmacy, and other federal and state agencies to complain about ImprimisRx. In December 2017, ImprimisRx received a warning letter from the FDA, relaying the agency's determination that the marketing of some of the company's eye drops contained false or misleading claims about efficacy and risks, allegedly in violation of federal law.
After a jury trial, Harrow (then Imprimis Pharmaceuticals) was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan having sought $60 million.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
HROW Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$41.66
Capitalizzazione di Mercato
$1.55B
P/E (TTM)
-297.5
EPS (TTM)
$-0.14
Ricavi (TTM)
$272M
Rendimento div.
—
ROE
-8.4%
D/E Debito/Patrimonio
—
Intervallo 52 sett.
$29 – $55
HROW Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$272M
2016-12-31
→
2025-12-31
EPS
$-0.14
2017-12-31
→
2025-12-31
Flusso di cassa libero
$43M
2016-12-31
→
2025-12-31
Margini
-1.9%
2016-12-31
→
2025-12-31
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
HROW
Mediana dei peer
P/E (TTM)
-297.5
31.7
P/S (TTM)
5.7
5.1
P/B
29.6
4.8
Price / FCF (Prezzo / FCF)
36.1
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
HROW
Mediana dei peer
Gross Margin (Margine lordo)
75.0%
74.1%
Operating Margin (Margine Operativo)
11.2%
—
Net Profit Margin (Margine di Profitto Netto)
-1.9%
-0.88%
ROA
-1.3%
-2.9%
ROE
-8.4%
-6.8%
ROIC
218.6%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
HROW
Mediana dei peer
Current Ratio (Rapporto corrente)
2.2
4.7
Quick Ratio
1.9
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
HROW
Mediana dei peer
Revenue YoY (Ricavi YoY)
36.4%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
45.4%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
41.0%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
HROW
Mediana dei peer
HROW Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
COMPRA
14 analisti
- Acquisto forte 5 35,7%
- Compra 8 57,1%
- Mantieni 1 7,1%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
8 analisti · 2026-08-18
Mediana
$61.50
Media
$67.50
← Sotto tutti i target
$41.66
Basso
$59.00
Alto
$88.00
Target mediano
$61.50
+47,6%
Target medio
$67.50
+62,0%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-0.18%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $-0.34 | $-0.18 | -0.16% |
| 31 Marzo 2026 | $-0.74 | $-0.41 | -0.33% |
| 31 Dicembre 2025 | $0.17 | $0.38 | -0.21% |
| 30 Settembre 2025 | $0.22 | $0.27 | -0.05% |
| 30 Giugno 2025 | $0.13 | $0.01 | 0.12% |
| 31 Marzo 2025 | $-0.50 | $-0.05 | -0.45% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| ANIP | $1.78B | 23.8 | 43.8% | 8.9% | 16.6% | — |
| ETON | $457M | — | 104.9% | -5.8% | -18.4% | 53.5% |
| AVLN | — | — | — | — | — | — |
| MAZE | $2.04B | -13.6 | — | — | -598.9% | — |
| LBRX | $563M | -7.1 | — | — | -25.5% | — |
| INVA | — | 6.1 | 14.7% | — | — | — |
| XERS | $1.30B | — | 43.7% | 0.19% | -19.7% | — |
| PAHC | — | 21.5 | 27.4% | 3.7% | 17.8% | 30.9% |
| ANRO | $568M | -8.1 | — | — | -46.1% | — |
| OMER | $1.23B | -343.6 | — | — | 1.9% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 18
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Cost of Revenue | $68M | $49M | $40M | $25M | $18M | $14M | $17M | $17M | $14M | · | · | · | |
| Gross Profit | $204M | $150M | $91M | $63M | $54M | $34M | $34M | $25M | $13M | $10M | $5M | $567.0K | |
| R&D Expense | $21M | $12M | $7M | $3M | $11M | $2M | $2M | $825.0K | $413.0K | $739.0K | $332.0K | $237.0K | |
| SG&A Expense | $153M | $129M | $83M | $58M | $41M | $31M | $33M | $29M | $25M | $18M | $13M | $8M | |
| Operating Expenses | $174M | $142M | $90M | $61M | $53M | $34M | $39M | $30M | $25M | · | · | · | |
| Operating Income | $31M | $9M | $431.0K | $2M | $2M | $385.0K | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M | |
| Interest Expense | · | · | $21M | $7M | $5M | · | · | · | · | · | · | $3.8K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $32.4K | |
| Other Non-op | $47.0K | $-185.0K | $-444.0K | $102.0K | $197.0K | $-73.0K | $630.0K | $103.0K | $-884.0K | $2M | $-1M | $29.0K | |
| Pretax Income | $-1M | $-17M | $-24M | $-14M | $-18M | $-3M | $-117.0K | $15M | $-13M | $-19M | · | · | |
| Income Tax | $4M | $161.0K | $701.0K | $75.0K | $133.0K | $4.0K | $8.0K | · | $-935.0K | $-111.0K | · | $3.0K | |
| Net Income | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| EPS (Basic) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 | $0.01 | $0.67 | $-0.60 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · | |
| Shares (Basic) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | 26,757,451 | 25,895,352 | 25,323,159 | 21,917,570 | 20,027,712 | · | · | · | |
| Shares (Diluted) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | · | 25,895,352 | 26,466,098 | 23,812,045 | 20,027,712 | · | · | · | |
| EBITDA | $32M | $10M | $1M | $3M | $3M | $2M | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M |
Stato Patrimoniale 27
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $73M | $47M | $74M | $96M | $42M | $4M | $5M | · | $4M | $9M | $3M | $8M | |
| Short-term Investments | · | · | $9M | $6M | $9M | $28M | · | · | · | · | · | · | |
| Receivables | $111M | $116M | $36M | $6M | $4M | $3M | $2M | $2M | $2M | $3M | $840.0K | $81.0K | |
| Inventory | $14M | $11M | $11M | $7M | $4M | $4M | $3M | $2M | $2M | $2M | $1M | $373.0K | |
| Prepaid Expense | $14M | $15M | $10M | $4M | $1M | $2M | $586.0K | $837.0K | $714.0K | $938.0K | $786.0K | $241.0K | |
| Other Current Assets | $2M | $3M | $2M | $118.0K | $92.0K | $190.0K | $105.0K | $125.0K | $124.0K | $106.0K | $119.0K | $35.0K | |
| Current Assets | $212M | $190M | $139M | $118M | $61M | $41M | $36M | $33M | $9M | $15M | $6M | $9M | |
| PP&E (Net) | $3M | $4M | $4M | $3M | $3M | $4M | $5M | $6M | $6M | $7M | $3M | $243.0K | |
| PP&E (Gross) | $15M | $15M | $14M | $13M | $11M | $10M | $11M | $11M | $9M | $9M | $3M | $288.0K | |
| Accum. Depreciation | $12M | $11M | $10M | $9M | $8M | $6M | $5M | $4M | $3M | $1M | $300.0K | $45.0K | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $2M | $2M | $2M | $2M | $332.0K | |
| Intangibles | $175M | $185M | $160M | $24M | $16M | $2M | $2M | $3M | $3M | $3M | $3M | $611.0K | |
| Total Assets | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Accounts Payable | $35M | $39M | $25M | $14M | $6M | $4M | $8M | $6M | $4M | $4M | $3M | $787.0K | |
| Short-term Debt | · | $220M | · | · | · | $4M | $2M | $3M | · | $4M | · | · | |
| Current Liabilities | $96M | $91M | $49M | $19M | $10M | $11M | $12M | $12M | $6M | $10M | $5M | $2M | |
| Capital Leases | $8M | $9M | $7M | $7M | $6M | $7M | $6M | · | $720.0K | $1M | $1.0K | $19.0K | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $936.0K | $1M | · | |
| Total Liabilities | $347M | $320M | $242M | $130M | $87M | $31M | $32M | $25M | $21M | $21M | $16M | $2M | |
| Long-term Debt | $250M | $263M | $247M | $152M | $103M | $20M | · | $23M | $23M | · | · | · | |
| Total Debt | · | · | · | · | · | $3M | $2M | $3M | · | $4M | · | · | |
| Common Stock | $37.0K | $35.0K | $35.0K | $30.0K | $27.0K | $26.0K | $26.0K | $24.0K | $21.0K | $19.0K | $10.0K | $9.0K | |
| Paid-in Capital | $209M | $221M | $205M | $137M | $107M | $105M | $102M | $99M | $91M | $83M | · | · | |
| Retained Earnings | $-157M | $-151M | $-134M | $-109M | $-95M | $-77M | $-74M | $-74M | $-89M | $-77M | $-58M | $-42M | |
| Stockholders' Equity | $52M | $70M | $71M | $28M | $11M | $27M | $28M | $25M | $3M | $6M | $-1M | $8M | |
| Liabilities + Equity | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Shares Outstanding | 37,229,159 | 35,622,214 | 35,168,260 | 29,901,530 | 26,902,763 | 25,749,875 | 25,526,931 | 24,339,610 | 20,623,129 | 18,627,915 | 9,755,678 | 9,258,231 |
Flusso di cassa 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $1M | $255.0K | $37.0K | |
| Stock-based Comp | $13M | $18M | $16M | $8M | $6M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $-935.0K | $-111.0K | · | · | |
| Amort. of Intangibles | $17M | $12M | $10M | $2M | $161.0K | $167.0K | $209.0K | $235.0K | $364.0K | $351.0K | $355.0K | $48.0K | |
| Other Non-cash | $35M | $-24M | $12M | $7M | $16M | $-2M | · | · | · | · | · | · | |
| Operating Cash Flow | $44M | $-22M | $4M | $2M | $5M | $-1M | $950.0K | $687.0K | $-9M | $-11M | $-11M | $-7M | |
| CapEx | $887.0K | $2M | $1M | $3M | $2M | $862.0K | $1M | $2M | $772.0K | $7M | $-995.0K | $174.0K | |
| Investing Cash Flow | $-5M | $-33M | $-153M | $-2M | $-19M | $-981.0K | $-2M | $-2M | $-961.0K | $-7M | $-5M | $-910.0K | |
| Stock Issued | · | · | $65M | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $-13.0K | |
| Net Stock Activity | · | · | · | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | $-13.1K | |
| Financing Cash Flow | $-13M | $29M | $127M | $54M | $51M | $1M | $-1M | $4M | $5M | $25M | $11M | $599.0K | |
| Net Change in Cash | $26M | $-27M | $-22M | $54M | $38M | $-648.0K | $-2M | $3M | $-5M | $6M | $-6M | $-7M | |
| Taxes Paid | $93.0K | $374.0K | · | $75.0K | $11.0K | $4.0K | $17.0K | $4.0K | $9.0K | $9.0K | $1.0K | $1.0K | |
| Free Cash Flow | $43M | $-24M | $2M | $-892.0K | $3M | $-2M | $-518.0K | $-1M | $-10M | $-4M | $-12M | $-7M | |
| Levered FCF | · | · | $-20M | $-8M | · | · | · | · | · | · | · | · |
Redditività 8
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% | 70.4% | 67.3% | 60.1% | 49.6% | 50.7% | 46.4% | 34.2% | |
| Operating Margin | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% | 0.79% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| Net Margin | -1.9% | -8.8% | -18.8% | -15.9% | -24.9% | -6.9% | 0.33% | 35.4% | -44.8% | -95.7% | -163.6% | -609.4% | |
| Pretax Margin | -0.50% | -8.7% | -18.2% | -15.8% | -24.7% | -7.0% | -0.24% | 35.4% | -48.3% | · | · | · | |
| EBITDA Margin | 11.7% | 5.1% | 1.1% | 3.6% | 4.4% | 4.6% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| ROA | -1.3% | -5.0% | -10.4% | -11.0% | -23.1% | -5.8% | 0.31% | 39.9% | -46.9% | -92.3% | -130.5% | -77.8% | |
| ROE | -8.4% | -24.9% | -49.6% | -72.5% | -93.6% | -12.2% | 0.64% | 117.8% | -265.0% | -756.4% | -470.0% | -87.0% | |
| ROIC | 218.6% | 12.8% | 0.63% | 7.0% | 14.4% | 1.3% | · | · | -431.5% | · | · | · |
Liquidità e Solvibilità 4
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 | 3.7 | 3.0 | 2.8 | 1.5 | 1.5 | 1.1 | 5.8 | |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 | 0.6 | 0.2 | 0.2 | 1.0 | 1.2 | 0.7 | 5.3 | |
| Debt / Equity | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | 0.6 | · | · | |
| Interest Coverage | · | · | 0.0 | 0.3 | · | · | · | · | · | · | · | -2670.2 |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.6 | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 | 0.8 | 0.1 | |
| Inventory Turnover | 5.6 | 4.6 | 4.6 | 4.7 | 4.5 | 4.0 | 6.5 | 8.1 | · | · | · | · | |
| Receivables Turnover | 2.4 | 2.6 | 6.1 | 16.5 | 20.3 | 20.9 | 26.1 | 24.0 | 12.0 | 10.6 | 21.1 | 40.8 |
Tassi di Crescita 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 36.4% | 53.3% | 46.9% | 22.2% | 48.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 45.4% | 40.2% | 38.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 41.0% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 14
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Net Income TTM | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| Market Cap | $1.82B | $1.20B | $394M | $441M | $232M | $177M | $199M | $138M | $35M | $47M | $68M | $69M | |
| Enterprise Value | · | · | · | · | · | $175M | · | · | · | $42M | · | · | |
| P/E | -350.0 | -68.5 | -14.9 | -28.9 | · | -52.8 | 778.0 | 9.3 | -2.8 | · | · | · | |
| P/S | 6.7 | 6.0 | 3.0 | 5.0 | 3.2 | 3.6 | 3.9 | 3.3 | 1.3 | 2.3 | 7.0 | 41.8 | |
| P/B | 34.8 | 17.2 | 5.6 | 16.0 | 20.6 | 6.5 | 7.2 | 5.6 | 13.4 | 7.2 | -48.8 | 8.5 | |
| P / Tangible Book | · | · | · | 124.7 | · | 7.1 | · | · | · | · | · | · | |
| P / Cash Flow | 41.6 | -53.8 | 102.6 | 258.9 | 45.7 | -160.6 | 209.1 | 201.6 | -4.0 | -4.2 | -6.1 | -9.8 | |
| P / FCF | 42.4 | -50.2 | 165.5 | -494.8 | 70.5 | -90.0 | -383.4 | -128.1 | -3.7 | -10.8 | -5.6 | -9.6 | |
| EV / EBITDA | · | · | · | · | · | 77.3 | · | · | · | -2.6 | · | · | |
| EV / FCF | · | · | · | · | · | -89.3 | · | · | · | -9.6 | · | · | |
| EV / Revenue | · | · | · | · | · | 3.6 | · | · | · | 2.1 | · | · | |
| Earnings Yield | -0.29% | -1.5% | -6.7% | -3.5% | · | -1.9% | 0.13% | 10.7% | -35.3% | · | · | · |
Conto Economico 17
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $44M | $89M | $72M | $64M | $48M | $67M | $49M | $49M | $35M | $36M | $34M | $33M | $26M | $20M | $23M | |
| Cost of Revenue | $20M | $17M | $18M | $18M | $16M | $16M | $14M | $12M | $13M | $11M | $11M | $10M | $10M | $8M | $6M | $7M | |
| Gross Profit | $50M | $27M | $71M | $54M | $48M | $32M | $53M | $37M | $36M | $24M | $25M | $24M | $23M | $18M | $14M | $16M | |
| R&D Expense | $8M | $6M | $12M | $3M | $3M | $3M | $5M | $2M | $3M | $2M | $3M | $1M | $1M | $734.0K | $703.0K | $775.0K | |
| SG&A Expense | $53M | $43M | $43M | $36M | $33M | $41M | $35M | $34M | $32M | $29M | $26M | $21M | $20M | $16M | $15M | $15M | |
| Operating Expenses | $61M | $49M | $55M | $39M | $36M | $44M | $40M | $36M | $35M | $31M | $30M | $22M | $21M | $17M | $16M | $16M | |
| Operating Income | $-11M | $-22M | $16M | $15M | $11M | $-11M | $13M | $1M | $2M | $-7M | $-5M | $2M | $2M | $1M | $-2M | $-94.0K | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $5M | · | $6M | $6M | $5M | $2M | $2M | |
| Other Non-op | $0 | · | $7M | $61.0K | $-6.0K | $-7M | $6M | $4.0K | $46.0K | $-7M | $-100.0K | $-195.0K | $-178.0K | $29.0K | · | · | |
| Pretax Income | $-17M | $-28M | $10M | $1M | $5M | $-18M | $6M | $-4M | $-6M | $-14M | $-10M | $-3M | $-4M | $-7M | $1M | $-6M | |
| Income Tax | $0 | $25.0K | · | · | $0 | · | $-514.0K | $20.0K | $655.0K | · | $-535.0K | $2M | $-15.0K | $-288.0K | $0 | $35.0K | |
| Net Income | $-17M | $-28M | $7M | $1M | $5M | $-18M | $7M | $-4M | $-6M | $-14M | $-9M | $-4M | $-4M | $-7M | $1M | $-6M | |
| EPS (Basic) | $-0.46 | $-0.74 | $0.19 | $0.03 | $0.14 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| EPS (Diluted) | $-0.46 | $-0.74 | $0.20 | $0.03 | $0.13 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| Shares (Basic) | 37,350,401 | 37,231,321 | -73,001,737 | 37,145,440 | 36,790,306 | 35,826,452 | -71,140,101 | 35,702,200 | 35,618,977 | 35,469,638 | -62,386,827 | 34,255,197 | 30,458,677 | 30,289,730 | -54,418,951 | 27,349,642 | |
| Shares (Diluted) | 37,350,401 | 37,231,321 | -76,794,851 | 38,875,005 | 38,853,855 | 35,826,452 | -71,140,101 | 35,702,200 | 35,618,977 | 35,469,638 | -62,386,827 | 34,255,197 | 30,458,677 | 30,289,730 | -54,418,951 | 27,349,642 | |
| EBITDA | $-11M | $-22M | · | $15M | $12M | $-11M | · | $1M | $2M | $-7M | · | $2M | $2M | $1M | · | $-94.0K |
Stato Patrimoniale 27
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84M | $95M | $73M | $74M | $53M | $67M | $47M | $73M | $71M | $69M | · | $66M | · | · | $96M | $45M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $7M | · | $8M | $7M | $8M | $6M | $4M | |
| Receivables | $119M | $101M | $111M | $78M | $79M | $77M | $116M | $54M | $52M | $29M | · | $18M | $18M | $12M | $6M | $7M | |
| Inventory | $17M | $16M | $14M | $13M | $12M | $11M | $11M | $10M | $9M | $11M | · | $9M | $9M | $9M | $7M | $5M | |
| Prepaid Expense | $10M | $14M | $14M | $13M | $12M | $15M | $15M | $11M | $7M | $10M | · | $9M | $4M | $4M | $4M | $3M | |
| Other Current Assets | $1M | $1M | $2M | $3M | $3M | $3M | $3M | $1M | $1M | $2M | · | $118.0K | $427.0K | $118.0K | $118.0K | $73.0K | |
| Current Assets | $229M | $226M | $212M | $178M | $155M | $170M | $190M | $147M | $139M | $125M | · | $110M | $60M | $52M | $118M | $64M | |
| PP&E (Net) | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | · | $4M | $4M | $4M | $3M | $3M | |
| PP&E (Gross) | · | · | $15M | $15M | $15M | $15M | $15M | $15M | $14M | $14M | · | $13M | $13M | $13M | $13M | $12M | |
| Accum. Depreciation | · | · | $12M | $12M | $12M | $11M | $11M | $11M | $11M | $10M | · | $10M | $10M | $9M | $9M | $9M | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | · | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | |
| Intangibles | $176M | $181M | $175M | $172M | $177M | $181M | $185M | $189M | $155M | $157M | · | $163M | $150M | $152M | $24M | $20M | |
| Total Assets | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Accounts Payable | $26M | $26M | $35M | $19M | $23M | $37M | $39M | $25M | $22M | $15M | · | $13M | $18M | $14M | $14M | $14M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $59.0K | · | · | · | · | |
| Short-term Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $102M | $91M | $96M | $65M | $249M | $187M | $91M | $95M | $54M | $42M | · | $19M | $23M | $18M | $19M | $18M | |
| Capital Leases | $7M | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $7M | $7M | · | $7M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $402M | $391M | $347M | $316M | $296M | $308M | $320M | $294M | $248M | $235M | · | $211M | $202M | $196M | $130M | $98M | |
| Long-term Debt | · | $300M | $250M | $347M | $251M | $257M | · | $231M | $236M | $243M | · | $252M | $240M | $244M | · | $98M | |
| Total Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $37.0K | $37.0K | $37.0K | $37.0K | $36.0K | $35.0K | $35.0K | $35.0K | $35.0K | $35.0K | · | $35.0K | $30.0K | $30.0K | $30.0K | $27.0K | |
| Paid-in Capital | $217M | $213M | $209M | $210M | $214M | $226M | $221M | $216M | $212M | $208M | · | $200M | $143M | $138M | $137M | $112M | |
| Retained Earnings | $-201M | $-184M | $-157M | $-163M | $-164M | $-169M | $-151M | $-158M | $-154M | $-147M | · | $-125M | $-120M | $-116M | $-109M | $-111M | |
| Stockholders' Equity | $15M | $29M | $52M | $47M | $50M | $56M | $70M | $58M | $59M | $61M | · | $76M | $22M | $22M | $28M | $1M | |
| Liabilities + Equity | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Shares Outstanding | 37,484,233 | 37,269,400 | 37,229,159 | 37,034,582 | 36,714,679 | 35,654,171 | 35,622,214 | 35,611,365 | 35,479,492 | 35,380,955 | · | 35,117,621 | 30,276,938 | 30,056,370 | 29,901,530 | 27,074,307 |
Flusso di cassa 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $460.0K | $455.0K | $330.0K | $326.0K | $347.0K | $312.0K | $321.0K | $351.0K | $301.0K | $296.0K | $435.0K | $405.0K | $398.0K | $225.0K | $387.0K | $247.0K | |
| Stock-based Comp | $4M | $4M | $4M | $3M | $875.0K | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $5M | $2M | $2M | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | $20.0K | · | · | · | · | $0 | $-288.0K | · | · | |
| Amort. of Intangibles | $6M | $5M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $3M | $2M | $378.0K | $398.0K | |
| Other Non-cash | · | · | · | · | · | $33M | · | · | · | $4M | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-9M | $8M | $17M | $-803.0K | $20M | $-18M | $3M | $-3M | $-5M | $9M | $-1M | $5M | $-8M | $-4M | $-410.0K | |
| CapEx | $491.0K | $194.0K | $341.0K | $210.0K | $166.0K | $170.0K | $555.0K | $604.0K | $344.0K | $92.0K | $194.0K | $520.0K | $250.0K | $496.0K | $878.0K | $1M | |
| Investing Cash Flow | $-534.0K | $-18M | $-5M | $-225.0K | $-293.0K | $-212.0K | $-38M | $-597.0K | $5M | $-110.0K | $-203.0K | $-20M | $-1M | $-131M | $-5.0K | $-1M | |
| Financing Cash Flow | $-466.0K | $49M | $-5M | $5M | $-13M | $23.0K | $30M | $-721.0K | $73.0K | $-809.0K | $-18.0K | $64M | $189.0K | $62M | $55M | $0 | |
| Net Change in Cash | $-11M | $22M | $-1M | $21M | $-14M | $19M | $-25M | $2M | $2M | $-6M | $8M | $43M | $4M | $-77M | $51M | $-1M | |
| Taxes Paid | · | · | $55.0K | $0 | $0 | $38.0K | · | · | · | · | · | · | · | · | $0 | $35.0K | |
| Free Cash Flow | · | $-9M | · | · | · | $19M | · | · | · | $-5M | · | · | · | $-9M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-13M | · | · |
Redditività 8
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.3% | 61.2% | · | 75.3% | 74.5% | 67.5% | · | 75.6% | 74.4% | 69.5% | · | 70.6% | 70.1% | 68.3% | · | 70.5% | |
| Operating Margin | -15.6% | -50.0% | · | 20.6% | 17.9% | -23.5% | · | 2.7% | 3.1% | -20.0% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| Net Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | -37.2% | · | -8.6% | -13.2% | -39.2% | · | -12.8% | -12.6% | -25.4% | · | -28.3% | |
| Pretax Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | · | · | -8.5% | -11.9% | -39.2% | · | -8.3% | -12.7% | -26.6% | · | -28.2% | |
| EBITDA Margin | -15.6% | -50.0% | · | 21.0% | 18.4% | -22.8% | · | 2.7% | 3.1% | -19.2% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| ROA | -4.5% | -7.0% | · | 0.29% | 1.5% | -5.4% | · | -1.3% | -2.4% | -5.3% | · | -2.3% | -2.6% | -4.2% | · | -6.4% | |
| ROE | -53.3% | -64.8% | · | 1.9% | 9.2% | -30.4% | · | -6.3% | -16.0% | -32.9% | · | -11.4% | -30.0% | -41.5% | · | -72.6% | |
| ROIC | -72.4% | -77.0% | · | · | · | · | · | 2.3% | 2.9% | · | · | 3.5% | 10.5% | 5.3% | · | -7.8% |
Liquidità e Solvibilità 4
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.5 | · | 2.7 | 0.6 | 0.9 | · | 1.5 | 2.6 | 3.0 | · | 5.8 | 2.6 | 2.9 | · | 3.5 | |
| Quick Ratio | 2.0 | 2.1 | · | 2.3 | 0.5 | 0.8 | · | 1.3 | 2.3 | 2.5 | · | 4.9 | 1.1 | 1.1 | · | 3.0 | |
| Debt / Equity | · | · | · | 5.2 | 3.7 | 1.9 | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.3 | · | 0.3 | 0.4 | 0.3 | · | -0.1 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.4 | · | 1.3 | 1.4 | 1.1 | · | 1.4 | 1.5 | 1.2 | · | 1.5 | |
| Receivables Turnover | 0.7 | 0.5 | · | 1.1 | 1.0 | 0.9 | · | 1.4 | 1.4 | 1.7 | · | 2.7 | 2.7 | 2.9 | · | 4.2 |
Valutazione (TTM) 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $250M | $227M | · | $232M | $210M | $181M | · | $167M | $151M | $128M | · | $117M | $106M | $94M | · | $87M | |
| Net Income TTM | $-39M | $-39M | · | $-16M | $-23M | $-42M | · | $-29M | $-29M | $-29M | · | $-22M | $-24M | $-22M | · | $-23M | |
| Market Cap | $1.59B | $1.31B | · | $1.78B | $1.12B | $948M | · | $1.60B | $741M | $468M | · | $505M | $576M | $636M | · | $327M | |
| Enterprise Value | · | · | · | $1.95B | $1.25B | $990M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -40.8 | -32.6 | · | -104.7 | -45.6 | -22.5 | · | -55.5 | -25.2 | -15.2 | · | -19.7 | -22.9 | -27.1 | · | -13.9 | |
| P/S | 6.4 | 5.8 | · | 7.7 | 5.3 | 5.3 | · | 9.6 | 4.9 | 3.6 | · | 4.3 | 5.5 | 6.7 | · | 3.8 | |
| P/B | 104.7 | 45.8 | · | 38.0 | 22.6 | 16.8 | · | 27.6 | 12.7 | 7.7 | · | 6.7 | 25.7 | 29.1 | · | 268.5 | |
| P / Cash Flow | · | -146.1 | · | · | · | 48.2 | · | · | · | -101.1 | · | · | · | -77.4 | · | · | |
| P / FCF | · | -143.1 | · | · | · | 48.6 | · | · | · | -99.2 | · | · | · | -73.0 | · | · | |
| EV / EBITDA | · | · | · | 129.6 | 106.5 | -90.7 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | 50.8 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | · | · | · | 8.4 | 6.0 | 5.5 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -2.5% | -3.1% | · | -0.95% | -2.2% | -4.4% | · | -1.8% | -4.0% | -6.6% | · | -5.1% | -4.4% | -3.7% | · | -7.2% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $272M | $200M | $130M | $89M | $72M |
| Margine Lordo % | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% |
| Margine Operativo % | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% |
| Utile netto | $-5M | $-17M | $-24M | $-14M | $-18M |
| EPS Diluito | $-0.14 | $-0.49 | $-0.75 | $-0.51 | — |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Rapporto corrente | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $43M | $-24M | $2M | $-892.0K | $3M |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 245 filer · $773.9M totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 49 (+3 vs trimestre precedente) | 34 (+4 vs trimestre precedente) | 74 (+1 vs trimestre precedente) | 67 (-4 vs trimestre precedente) | -146K |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| Opaleye Management Inc. | $101.928.000 | 2.400.000 | 13,17% | Azioni |
| Private Capital Management, LLC | $67.899.762 | 1.598.770 | 8,77% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $60.188.994 | 1.417.212 | 7,78% | Azioni |
| Deep Track Capital, LP | $41.153.430 | 969.000 | 5,32% | Azioni |
| STATE STREET CORP | $39.917.043 | 939.888 | 5,16% | Azioni |
| BAMCO INC /NY/ | $34.373.094 | 809.350 | 4,44% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $33.342.270 | 784.905 | 4,31% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31.550.963 | 742.900 | 4,08% | Opzione Call |
| DIMENSIONAL FUND ADVISORS LP | $26.788.590 | 630.765 | 3,46% | Azioni |
| Divisadero Street Capital Management, LP | $18.650.913 | 439.155 | 2,41% | Azioni |
| CITADEL ADVISORS LLC | $16.622.758 | 391.400 | 2,15% | Opzione Call |
| RICE HALL JAMES & ASSOCIATES, LLC | $16.459.036 | 387.545 | 2,13% | Azioni |
| Schonfeld Strategic Advisors LLC | $13.574.473 | 319.625 | 1,75% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13.531.367 | 318.610 | 1,75% | Azioni |
| MARSHALL WACE, LLP | $12.157.037 | 286.250 | 1,57% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11.623.869 | 273.696 | 1,50% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $9.998.202 | 235.418 | 1,29% | Azioni |
| CITADEL ADVISORS LLC | $9.895.510 | 233.000 | 1,28% | Opzione Put |
| Westside Investment Management, Inc. | $9.473.007 | 223.051 | 1,22% | Azioni |
| FirstWave Capital Management LLC | $9.002.833 | 211.981 | 1,16% | Azioni |
| Blackhawk Capital Partners, LLC | $8.631.645 | 203.241 | 1,12% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8.074.227 | 190.116 | 1,04% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7.827.221 | 184.300 | 1,01% | Opzione Put |
| JANE STREET GROUP, LLC | $7.772.010 | 183.000 | 1,00% | Opzione Call |
| ROYCE & ASSOCIATES LP | $6.565.310 | 154.587 | 0,85% | Azioni |
| Ikarian Capital, LLC | $5.766.364 | 135.775 | 0,75% | Azioni |
| Advantage Alpha Capital Partners LP | $5.374.624 | 111.553 | 0,69% | Azioni |
| Diametric Capital, LP | $4.965.082 | 116.908 | 0,64% | Azioni |
| WOODMONT INVESTMENT COUNSEL LLC | $4.748.571 | 111.810 | 0,61% | Azioni |
| FIRST TRUST ADVISORS LP | $4.260.378 | 100.315 | 0,55% | Azioni |
| STATE OF WISCONSIN INVESTMENT BOARD | $4.146.219 | 97.627 | 0,54% | Azioni |
| 12th Street Asset Management Company, LLC | $3.882.140 | 91.409 | 0,50% | Azioni |
| Lumbard & Kellner, LLC | $3.835.975 | 90.322 | 0,50% | Azioni |
| Steward Partners Investment Advisory, LLC | $3.832.960 | 90.251 | 0,50% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $3.575.210 | 84.182 | 0,46% | Azioni |
| EQUITABLE TRUST CO | $3.371.184 | 79.378 | 0,44% | Azioni |
| BANK OF AMERICA CORP /DE/ | $3.138.533 | 73.900 | 0,41% | Azioni |
| Squarepoint Ops LLC | $3.126.726 | 73.622 | 0,40% | Azioni |
| KENNEDY CAPITAL MANAGEMENT LLC | $3.004.668 | 70.748 | 0,39% | Azioni |
| Swiss National Bank | $2.696.845 | 63.500 | 0,35% | Azioni |
| CITADEL ADVISORS LLC | $2.533.888 | 59.663 | 0,33% | Azioni |
| Jefferson Bridge Capital, LLC | $2.427.925 | 57.168 | 0,31% | Azioni |
| CAPTRUST FINANCIAL ADVISORS | $2.395.903 | 56.414 | 0,31% | Azioni |
| Militia Capital Partners, LP | $2.303.000 | 47.000 | 0,30% | Azioni |
| PRINCIPAL FINANCIAL GROUP INC | $2.288.921 | 53.895 | 0,30% | Azioni |
| GROUP ONE TRADING LLC | $2.085.914 | 49.115 | 0,27% | Azioni |
| LJI Wealth Management, LLC | $2.021.572 | 47.600 | 0,26% | Azioni |
| JANE STREET GROUP, LLC | $2.000.337 | 47.100 | 0,26% | Opzione Put |
| RENAISSANCE TECHNOLOGIES LLC | $1.894.884 | 44.617 | 0,24% | Azioni |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $1.863.796 | 43.885 | 0,24% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $1.841.542 | 43.361 | 0,24% | Azioni |
| RHUMBLINE ADVISERS | $1.739.772 | 40.965 | 0,22% | Azioni |
| BARD ASSOCIATES INC | $1.716.171 | 40.409 | 0,22% | Azioni |
| BLAIR WILLIAM & CO/IL | $1.693.704 | 39.880 | 0,22% | Azioni |
| LPL Financial LLC | $1.547.267 | 36.432 | 0,20% | Azioni |
| Campbell & CO Investment Adviser LLC | $1.541.066 | 36.286 | 0,20% | Azioni |
| D.A. DAVIDSON & CO. | $1.471.586 | 34.650 | 0,19% | Azioni |
| BOOTHBAY FUND MANAGEMENT, LLC | $1.417.351 | 33.373 | 0,18% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $1.390.549 | 39.437 | 0,18% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $1.375.810 | 39.019 | 0,18% | Azioni |
| STANSBERRY ASSET MANAGEMENT, LLC | $1.360.399 | 32.032 | 0,18% | Azioni |
| GOLDMAN SACHS GROUP INC | $1.330.713 | 31.333 | 0,17% | Azioni |
| Brookstone Capital Management | $1.323.068 | 31.153 | 0,17% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $1.273.208 | 29.979 | 0,16% | Azioni |
| GREAT LAKES ADVISORS, LLC | $1.145.119 | 26.963 | 0,15% | Azioni |
| KORNITZER CAPITAL MANAGEMENT INC /KS | $1.117.556 | 26.314 | 0,14% | Azioni |
| BlackRock, Inc. | $1.115.899 | 26.275 | 0,14% | Azioni |
| Crawford Fund Management, LLC | $1.113.563 | 26.220 | 0,14% | Azioni |
| Bank of New York Mellon Corp | $1.109.571 | 26.126 | 0,14% | Azioni |
| OSAIC HOLDINGS, INC. | $1.066.373 | 25.109 | 0,14% | Azioni |
| ENVESTNET ASSET MANAGEMENT INC | $1.063.406 | 25.039 | 0,14% | Azioni |
| ExodusPoint Capital Management, LP | $1.029.600 | 24.243 | 0,13% | Azioni |
| Bleakley Financial Group, LLC | $1.022.125 | 24.067 | 0,13% | Azioni |
| Birchview Capital, LP | $1.019.280 | 24.000 | 0,13% | Azioni |
| XTX Topco Ltd | $983.053 | 23.147 | 0,13% | Azioni |
| Focus Partners Wealth | $979.826 | 23.071 | 0,13% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $954.556 | 22.476 | 0,12% | Azioni |
| COMMERCE BANK | $952.602 | 22.430 | 0,12% | Azioni |
| Squarepoint Ops LLC | $925.846 | 21.800 | 0,12% | Opzione Put |
| VANGUARD ASSET MANAGEMENT, Ltd | $904.399 | 21.295 | 0,12% | Azioni |
| IMC-Chicago, LLC | $886.646 | 20.877 | 0,11% | Azioni |
| FineMark National Bank & Trust | $854.070 | 17.430 | 0,11% | Azioni |
| Sonora Investment Management Group, LLC | $826.191 | 17.148 | 0,11% | Azioni |
| CORSAIR CAPITAL MANAGEMENT, L.P. | $806.930 | 19.000 | 0,10% | Azioni |
| MetLife Investment Management, LLC | $803.023 | 18.908 | 0,10% | Azioni |
| Private Capital Management, LLC | $743.225 | 17.500 | 0,10% | Opzione Call |
| Round Rock Advisors LLC | $742.418 | 17.481 | 0,10% | Azioni |
| MML INVESTORS SERVICES, LLC | $707.805 | 16.666 | 0,09% | Azioni |
| Lido Advisors, LLC | $700.288 | 16.489 | 0,09% | Azioni |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $692.091 | 16.296 | 0,09% | Azioni |
| Atria Investments, Inc | $683.215 | 16.087 | 0,09% | Azioni |
| UBS Group AG | $672.640 | 15.838 | 0,09% | Azioni |
| BARCLAYS PLC | $672.215 | 15.828 | 0,09% | Azioni |
| SIMPLEX TRADING, LLC | $651.872 | 15.349 | 0,08% | Azioni |
| ARISTEIA CAPITAL, L.L.C. | $651.702 | 15.345 | 0,08% | Azioni |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $633.270 | 14.911 | 0,08% | Azioni |
| VANGUARD GROUP INC | $617.155 | 12.595 | 0,08% | Azioni |
| Grandeur Peak Global Advisors, LLC | $609.572 | 14.353 | 0,08% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $600.441 | 14.138 | 0,08% | Azioni |
| Walleye Partners, LLC | $572.369 | 13.477 | 0,07% | Azioni |
Insider aziendali 20 insider · 5 dirigenti · 11 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Mark L. Baum | Chief Executive Officer | 10 Febbraio 2014 A | 1.419.835 | 0 | 0 | $0 |
| Juliet Singh | CEO, Director and President | 18 Giugno 2009 A | 1.954.125 | 0 | 0 | $0 |
| Andrew Boll | VP, Accounting and Reporting | 10 Febbraio 2014 A | — | 0 | 0 | $0 |
| Joachim Ph Schupp | CHIEF MEDICAL OFFICER | 01 Aprile 2013 A | — | 0 | 0 | $0 |
| Terry Nida | Chief Business Officer | 26 Febbraio 2010 A | — | 0 | 0 | $0 |
| Perry J. Sternberg | Direttore | 18 Giugno 2026 A | — | 0 | 0 | $0 |
| Adrienne L Graves | Direttore | 18 Giugno 2026 A | — | 0 | 0 | $0 |
| Lauren P Silvernail | Direttore | 18 Giugno 2026 A | — | 0 | 0 | $0 |
| Peter C Kenny | Direttore | 02 Ottobre 2013 A | 8.947 | 0 | 0 | $0 |
| Robert J Kammer | Direttore | 28 Giugno 2013 A | 931.689 | 0 | 0 | $0 |
| August Shelby Bassani | Direttore | 27 Giugno 2013 A | 6.865 | 0 | 0 | $0 |
| Paul Finnegan | Direttore | 27 Giugno 2013 A | 6.865 | 0 | 0 | $0 |
| Jeffrey J Abrams | Direttore | 27 Giugno 2013 A | 45.927 | 0 | 0 | $0 |
| Stephen G Austin | Direttore | 27 Giugno 2013 A | 6.865 | 0 | 0 | $0 |
| DERMASTAR INTERNATIONAL, LLC | Proprietario del 10% | 12 Luglio 2012 J | 0 | 0 | 0 | $0 |
| Amir Shojaei | — | 14 Agosto 2026 M | 0 | 0 | 1 | $-450.000 |
| John N Bonfiglio | — | 20 Ottobre 2010 A | 50.000 | 0 | 0 | $0 |
| John T Lomoro | — | 19 Giugno 2009 A | — | 0 | 0 | $0 |
| Lynn C Swann | — | 21 Novembre 2008 A | 25.000 | 0 | 0 | $0 |
| Anthony S Thornley | — | 21 Novembre 2008 A | 60.900 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 5 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Mark L. Baum ×3 depositi | 07 Aprile 2025 | 10,69% | Modifica | — | SEC |
| 27 Aprile 2021 | — | Deposito iniziale | — | SEC | |
| Robert J. Kammer, as Trustee of The Robert J. Kammer Living Trust established 6/1/2000, Robert J. Kammer ×2 depositi | 30 Agosto 2016 | — | Deposito iniziale | Investimento passivo | SEC |
| Dr. Robert J. Kammer ×2 depositi | 16 Agosto 2013 | — | Deposito iniziale | — | SEC |
| DermaStar International, LLC ×7 depositi | 10 Agosto 2012 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 47 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,47% | 4.670 NS | 30 Aprile 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,26% | 66.235 NS | 30 Aprile 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,10% | 28.159 NS | 31 Maggio 2026 | N-PORT |
| PSC · Principal Exchange-Traded Funds | 0,10% | 53.287 NS | 30 Giugno 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,08% | 48.827 NS | 30 Aprile 2026 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,07% | 19.636 NS | 30 Aprile 2026 | N-PORT |
| BIB · ProShares Trust | 0,07% | 1.370 NS | 31 Maggio 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,06% | 10.343 NS | 30 Aprile 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 6.175 NS | 30 Aprile 2026 | N-PORT |
| RSSL · Global X Funds | 0,04% | 13.694 NS | 30 Aprile 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,04% | 123.278 NS | 30 Aprile 2026 | N-PORT |
| ITWO · ProShares Trust | 0,03% | 1.486 NS | 31 Maggio 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,02% | 158.672 NS | 31 Maggio 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,02% | 18.041 NS | 31 Maggio 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 14.677 NS | 30 Aprile 2026 | N-PORT |
| UWM · ProShares Trust | 0,02% | 1.162 NS | 31 Maggio 2026 | N-PORT |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,01% | 860 NS | 31 Maggio 2026 | N-PORT |
| URTY · ProShares Trust | 0,01% | 1.174 NS | 31 Maggio 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,01% | 949 NS | 30 Aprile 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 1.223 NS | 31 Maggio 2026 | N-PORT |
| EBI · RBB Fund Trust | 0,01% | 984 NS | 31 Maggio 2026 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,00% | 18.264 NS | 31 Maggio 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 29 NS | 31 Maggio 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 50.366 NS | 30 Aprile 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,00% | 11.315 NS | 31 Maggio 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 8.641 NS | 30 Aprile 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1.856 NS | 30 Aprile 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 11.363 NS | 30 Aprile 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 19.602 NS | 31 Maggio 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 Luglio 2026 | Giornaliero |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 Luglio 2026 | Giornaliero |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Luglio 2026 | Giornaliero |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Luglio 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Luglio 2026 | Giornaliero |
| ITOT · iShares Trust | — | — | 05 Agosto 2026 | Giornaliero |
| IWV · iShares Trust | — | — | 18 Agosto 2026 | Giornaliero |
| IWO · iShares Trust | — | — | 18 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | — | — | 18 Agosto 2026 | Giornaliero |
| IWC · iShares Trust | — | — | 18 Agosto 2026 | Giornaliero |
| IHE · iShares Trust | — | — | 18 Agosto 2026 | Giornaliero |
| OMFS · Invesco Exchange-Traded Self-Indexe… | — | — | 13 Luglio 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | — | — | 20 Luglio 2026 | Giornaliero |
| ISCB · iShares Trust | — | — | 05 Agosto 2026 | Giornaliero |
| ISCG · iShares Trust | — | — | 05 Agosto 2026 | Giornaliero |
| SMLF · iShares Trust | — | — | 10 Agosto 2026 | Giornaliero |
| WSML · iShares Trust | — | — | 05 Agosto 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | — | — | 05 Agosto 2026 | Giornaliero |